Xintela publishes results from glioblastoma study

#Regulatory

Read PDF

Lund, Sweden, 26 April 2019 – Xintela announces that the results of the company's glioblastoma study have now been published in the renowned international scientific journal Cancers. The publication demonstrates and discusses that Xintela's marker, integrin α10β1, regulates important functions of glioblastoma cells and is a potential new therapeutic target for the treatment of the highly aggressive brain tumor glioblastoma.

Glioblastoma is the most common and most aggressive brain tumor form in adults and there is a enormous need for new and better treatment strategies. Xintela has previously reported positive preclinical results in which an antibody directed against the company's marker integrin α10β1 and combined with a cell toxin (Antibody-Drug Conjugate, ADC) was able to kill glioblastoma cells, both in cell experiments and in an animal model. The article now published, demonstrates that integrin α10β1 is highly expressed on cells in glioblastoma tumors but not in normal brain tissue and that the integrin has an important functional role on the glioblastoma cells by regulating cell migration (movement), growth and survival. In addition, the results show that an ADC directed to integrin α10β1 can block the function of glioblastoma cells and lead to the killing of the glioblastoma cells both in cell experiments and in an animal model. These results demonstrate the potential of the Xintela marker integrin α10β1 as a novel therapeutic target for the treatment of glioblastoma.

“We are very pleased that our results have now been published in the renowned international scientific journal Cancers. This is very positive in our discussions with potential investors and partners in the development of a First-in-Class therapy for glioblastoma and other high-grade, aggressive tumors”, says Xintela's CEO Evy Lundgren-Åkerlund.

The publication:
Integrin α10, a Novel Therapeutic Target in Glioblastoma, Regulates Cell Migration, Proliferation, and Survival by Matilda Munksgaard Thorén, Katarzyna Chmielarska Masoumi, Cecilia Krona, Xiaoli Huang, Soumi Kundu, Linnéa Schmidt, Karin Forsberg-Nilsson, Marcus Floyd Keep, Elisabet Englund, Sven Nelander, Bo Holmqvist and Evy Lundgren-Åkerlund. Cancers 2019, 11(4), 587.

To read the publication, visit: https://doi.org/10.3390/cancers11040587

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: 070-329 18 71
Email: evy@xintela.se
Medicon Village
223 81 Lund
www.xintela.se

About Xintela
Xintela develops medical products within regenerative medicine and oncology based on its proprietary marker technology, XINMARK®. Xintela uses the technology to isolate and quality assure stem cells for the treatment of the joint disease osteoarthritis. Studies on horses have shown that the stem cells are safe and that they have a therapeutic effect on the articular cartilage and the underlying bone after an injury. Xintela has recently established its own GMP-facility to produce stem cells for clinical studies. In the oncology program, XINMARK® is used for the development of an antibody-based treatment (Antibody Drug Conjugate, ADC) against specific tumors with first focus on the aggressive brain tumor glioblastoma. Positive preclinical results from cell studies and animal model have shown that the ADC treatment has a targeting and killing effect on specific tumor cells supporting further development of the company’s oncology business. Xintela is listed on Nasdaq First North Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.

Archive

Below you will find the collected information on Xintela’s press releases, newsletters, diary events, films, media coverage and analyses.

June 13, 2022
Bio International Convention, San Diego, June 13-16
Bio International Convention, San Diego, June 13-16
June 13, 2022
Småbolagsdagarna, Stockholm, June 13-15
Småbolagsdagarna, Stockholm, June 13-15
June 14, 2022

CEO Evy Lundgren-Åkerlund presents the company at Aktiespararnas Småbolagsdagarna 2022 (in Swedish).

June 14, 2022

Targinta's CEO Per Norlén presents the company at Aktiespararnas Småbolagsdagarna 2022 (in Swedish).

June 9, 2022

CEO Evy Lundgren-Åkerlund presents the company at BioStock Life Science Spring Summit 2022.

February 27, 2020

BioStock interview with Xintela's CMO and board member Sven Kili.

August 30, 2018

BioStock was given the opportunity to interview Sven Kili in connection with his visit to Sweden for board and strategy work in Xintela.

February 9, 2017

Dr. Marcus Keep comments on Xintelas glioblastoma project.

January 31, 2017

Xintelas Chairman of the board and strategic advisor Greg Batcheller, tells us more about Xintelas potential and prospects.

January 30, 2017

Dr. Lisa Fortier at Cornell University, New York is interviewed by BioStock about Xintelas positive results in horse study.

December 28, 2016

In the following video interview, Karin explains her role at Xintela and what she considers to be Xintela’s primary strengths.

December 13, 2016

See the interview with Claes Post, member of the board in Xintela. The interview is in swedish with english subtitles.

March 24, 2016

See the interview with Sven Kili, member of the board in Xintela. The interview is in English (introduction is in Swedish).

March 22, 2016

See an interview with Xintela's CEO Evy Lundgren-Åkerlund, after the listing ceremony at Nasdaq First North.

March 15, 2016

Investor presentation from Lund - Jan 27

January 14, 2016

Interview with Xintelas CEO

June 1, 2022
BioStock Studio: Xintela's CEO comments on the upcoming share issue
April 12, 2022
BioStock: Xintela's CEO on the potential in difficult-to-heal wounds
March 4, 2022
BioStock: Xintela presents plans for 2022 in its Q4 report
January 27, 2022
BioStock Studio: Targinta provides business update prior to spin-off
January 19, 2022
BioStock: Xintela advances to clinical phase in osteoarthritis and difficult-to-heal wounds 2022
October 12, 2021
BioStock: Professor Folke Sjöberg about XSTEM for treatment of venous leg ulcers.
November 9, 2020
BioStock: Xintela’s CEO comments on the positive patent notice
June 22, 2017
Xintela covered in GEN regarding its participation in multi-million, government funded initiative to form a...
March 2, 2017
Xintela covered in Horsetalk.co.nz regarding that its stem cells are safe for use in horses
March 23, 2016
(Article in Swedish) Xintela tar behandling av ledskador och cancer till First North.
March 23, 2016
(Article in Swedish) Grundare av Xintela ser notering som viktig milstolpe
March 23, 2016
(Article in Swedish) Xintela covered in Life Science Sweden
February 24, 2016
(Article in Swedish) Rapidus: Xintela på väg till First North
December 10, 2021
Edison Group has published a research update on Xintela.
July 14, 2021
Xintela, backed by its integrin biomarker technology platform XINMARK, is a potential disrupter
November 9, 2020
A status report of the Xintela has been published by Biostock
April 12, 2018
Read the full analysis here
Top